SARS-CoV-2 innate immunity evasion and cell-specific immune response (WP5039)

Homo sapiens

Authors

Mario Alin Rus , Egon Willighagen , Nuray Talih , Martina Summer-Kutmon , Friederike Ehrhart , Eric Weitz , Nhung Pham , and Lars Willighagen

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• The Biological Interaction of SARS-CoV-2 Infection and Osteoporosis: A Preliminary Study (2022).
• Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies (2022).
• Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood (2022).
• Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients (2024).
• Combination of Enrichment Using Gene Ontology and Transcriptomic Analysis Revealed Contribution of Interferon Signaling to Severity of COVID-19 (2022).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

COVID-19

Annotations

Pathway Ontology

disease pathway immune response pathway

Disease Ontology

severe acute respiratory syndrome COVID-19

References

1. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein [Internet]. Wang K, Chen W, Zhou YS, Lian JQ, Zhang Z, Du P, et al. Cold Spring Harbor Laboratory; 2020. Available from: http://dx.doi.org/10.1101/2020.03.14.988345 DOI Scholia
2. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients [Internet]. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Péré H, et al. Cold Spring Harbor Laboratory; 2020. Available from: http://dx.doi.org/10.1101/2020.04.19.20068015 DOI Scholia
3. SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98 [Internet]. Addetia A, Lieberman NAP, Phung Q, Xie H, Roychoudhury P, Shrestha L, et al. Cold Spring Harbor Laboratory; 2020. Available from: http://dx.doi.org/10.1101/2020.08.03.234559 DOI Scholia
4. Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes during COVID-19 Infection. Wei L, Ming S, Zou B, Wu Y, Hong Z, Li Z, et al. SSRN Journal [Internet]. 2020; Available from: http://dx.doi.org/10.2139/ssrn.3555695 DOI Scholia
5. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, et al. Oncogene. 2005 Jan 20;24(4):605–15. PubMed Europe PMC Scholia
6. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. Zhang X, Wu K, Wang D, Yue X, Song D, Zhu Y, et al. Virology. 2007 Sep 1;365(2):324–35. PubMed Europe PMC Scholia
7. Coronaviruses post-SARS: update on replication and pathogenesis. Perlman S, Netland J. Nat Rev Microbiol. 2009 Jun;7(6):439–50. PubMed Europe PMC Scholia
8. Recent advances in the anti-HCV mechanisms of interferon. Huang M, Jiang JD, Peng Z. Acta Pharm Sin B. 2014 Aug;4(4):241–7. PubMed Europe PMC Scholia
9. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Lancet. 2020 Feb 15;395(10223):497–506. PubMed Europe PMC Scholia
10. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. Nature. 2020 Jul;583(7816):459–68. PubMed Europe PMC Scholia
11. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Cell. 2020 May 28;181(5):1036-1045.e9. PubMed Europe PMC Scholia
12. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Yuen CK, Lam JY, Wong WM, Mak LF, Wang X, Chu H, et al. Emerg Microbes Infect. 2020 Dec;9(1):1418–28. PubMed Europe PMC Scholia
13. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M, et al. Cell Mol Immunol. 2020 Aug;17(8):881–3. PubMed Europe PMC Scholia
14. Covid-19: Perspectives on Innate Immune Evasion. Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. Front Immunol. 2020 Sep 30;11:580641. PubMed Europe PMC Scholia
15. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Ahmad T, Chaudhuri R, Joshi MC, Almatroudi A, Rahmani AH, Ali SM. Front Microbiol. 2020 Dec 1;11:588409. PubMed Europe PMC Scholia
16. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Zheng Y, Zhuang MW, Han L, Zhang J, Nan ML, Zhan P, et al. Signal Transduct Target Ther. 2020 Dec 28;5(1):299. PubMed Europe PMC Scholia
17. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Front Immunol. 2020 Dec 16;11:610300. PubMed Europe PMC Scholia